Malignant pleural mesothelioma: from the bench to the bedside.
about
The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of MesotheliumMDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesotheliomaCurcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line.CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcomeChanging pattern in malignant mesothelioma survivalBlockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo modelUnusual presentation and location pleural malignant mesothelioma.Application of capillary electrophoresis for the early diagnosis of cancer.A catalogue of treatment and technologies for malignant pleural mesothelioma.Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsRole of new radiation techniques in the treatment of pleural mesothelioma.Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
P2860
Q26750451-F3560460-BE61-4CE4-B813-7BF01DA2F88BQ27853125-07846339-B7FF-4EB9-87D4-6A316E48D871Q33555260-D55FEF22-E9C0-42B9-A117-17DFC986625DQ33798391-AC16B3BF-3BD1-410D-86FB-333E4EBFC7CEQ34227644-5B968B67-1C5E-4105-AE8D-EC4528E2D72EQ35150628-9C970B73-E42A-4266-818D-96FA1D8F4AC2Q35189370-E5115204-F9CC-45EE-BCDB-D5FEA459D716Q36986796-752502CE-7F58-4ABE-8AEB-8D37A2C24726Q38199367-56D93D9F-7135-4E74-B3A3-F97B2A9A748AQ38760623-3217E055-1E37-4873-A7AA-DAC2AC3D65AEQ38983373-1A415FBB-B0F6-4977-87E4-A085A8CC68B6Q41905649-7C47CA3D-7FB8-40A0-AEEB-E1632AEFC4C9Q42038363-71866A97-9E12-4FB3-AAE2-748A7A7B8E77Q50050392-EC3D39B4-5E45-47C9-8372-206E96F55BC4Q56976088-1A41003A-22BD-45C6-BB88-51736F509C6E
P2860
Malignant pleural mesothelioma: from the bench to the bedside.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Malignant pleural mesothelioma: from the bench to the bedside.
@en
type
label
Malignant pleural mesothelioma: from the bench to the bedside.
@en
prefLabel
Malignant pleural mesothelioma: from the bench to the bedside.
@en
P2093
P2860
P356
P1433
P1476
Malignant pleural mesothelioma: from the bench to the bedside
@en
P2093
A Scherpereel
F Galateau-Salle
P2860
P304
P356
10.1159/000339259
P50
P577
2012-06-15T00:00:00Z